Floatz logo

Igf-Methotrexate Conjugate

Leukemia, Myelomonocytic, Chronic

IGF Oncology, LLCunclassifiedPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Leukemia, Myelomonocytic, Chronic cohort.

Asset / SponsorPhaseRating
Pevonedistat
Takeda
Phase 3BB
Decitabine
Otsuka Australia Pharmaceutical Pty Ltd
Phase 3B
rft5-smpt-dga
National Heart, Lung, and Blood Institute (NHLBI)
Phase 2B
h3b-8800
Hemavant Sciences GmbH
Phase 1CC

Same molecule, other indications

Igf-Methotrexate Conjugate is also rated in:

Anemia, Refractory, With Excess of BlastsDormant
CCC
Indicative ·
48 / 100
View asset →
thoracic cancerDormant
CC
Indicative ·
47 / 100
View asset →
malignant urinary system neoplasmDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →